Navigation Links
Omnicell Reports Strong Q3 Revenue and Profit Growth

MOUNTAIN VIEW, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Omnicell, Inc. (Nasdaq: OMCL), a leading provider of system solutions to acute healthcare facilities, today announced results for its third quarter ended September 30, 2007.

GAAP results: Revenues for the third quarter of 2007 totaled $55.2 million, up $3.3 million or 6.4% from second quarter 2007 revenue of $51.8 million, and up $13.9 million or 33.8% from the third quarter of 2006.

Third quarter 2007 net income as reported in accordance with U.S. generally accepted accounting principles (GAAP) was $6.9 million, or $0.19 per fully diluted share. Third quarter net income compares to net income of $18.1 million, or $0.55 per fully diluted share in the second quarter of 2007, including $12.8 million of income tax benefits related to the partial reversal of our tax valuation allowance in the second quarter of 2007; and $3.1 million, or $0.11 per fully diluted share in the third quarter of 2006. For the first nine months of 2007, net income was $29.0 million, or $0.88 per fully diluted share, of which $0.39 is represented by the same $12.8 million of income tax benefits related to the partial reversal of our tax valuation allowance in the second quarter of 2007. This compares to net income of $6.3 million or $0.22 per fully diluted share for the first nine months of 2006. Product backlog grew to $140.6 million, up $9.1 million from the quarter ended June 30, 2007.

Non-GAAP results: Excluding the impact on our results of recording $2.8 million in share-based compensation expenses related to SFAS No. 123R, non- GAAP net income was $9.8 million for the quarter ended September 30, 2007, or $0.27 per fully diluted share. This compares to non-GAAP income 15,308 17,658 13,964

Obligation resulting from

sale of receivables 398 596 1,093

Total current liabilities 49,623 48,839 53,556

Long-term deferred service

revenue 14,676 13,341 10,083

Other long-term liabilities 327 439 995

Total Liabilities 64,626 62,619 64,634

Stockholders' equity 230,288 215,053 89,996

Total Liabilities and

Stockholders' Equity $294,914 $277,672 $154,630

(1) Information derived from the audited Consolidated Financial


Reconciliation of GAAP to Non-GAAP

(in thousands, except for per share data, unaudited)

Three months ended

Sep 30, 2007 Sep 30, 2006 June 30, 2007

Earnings Earnings Earnings

per per per

Net share- Net share- Net share-

income diluted income diluted income diluted

GAAP $6,940 $0.19 $3,116 $0.11 $18,093 $0.55







Margin 294 304 331


Expenses 2,522 1,746 2,207

Income tax

adjustment(b) (12,784)

2,816 $0.08 2,050 $0.07 (10,246) ($0.31)

Non-GAAP $9,756 $0.27 $5,166 $0.18 $7,847 $0.24

Nine months ended

Sep 30, 2007 Sep 30, 2006

Earnings Earnings

per per

Net share- Net share-

Income diluted Income diluted

GAAP $28,998 $0.88 $6,265 $0.22







Margin 1,028 828


Expenses 7,049 5,288

Income tax


($4,707) $0.14 $6,116 $0.21

Non-GAAP $24,291 $0.74 $12,381 $0.43

(a) This adjustment reflects the accounting impact of non-cash share-based

compensation expense related to the impact of SFAS No.123R for the

three and nine months ended September 30, 2007 and 2006.

(b) This adjustment reflects the accounting impact of income tax provision

and tax benefit from release of valuation allowance reserve for the

three and nine months ended September 30, 2007. There was no

adjustment for the comparable period in 2006.

of $7.9 million or $0.24 per fully diluted share for the second quarter of 2007 and third quarter 2006 non-GAAP net income of $5.2 million or $0.18 per fully diluted share. Excluding $8.0 million in share-based compensation expenses related to SFAS No.123R and $12.8 million in income tax benefits related to a partial reversal of our tax valuation allowance, non-GAAP net income was $24.3 million for the nine months ended September 30, 2007, or $0.74 per fully diluted share. This compares to non-GAAP net income of $12.4 million or $0.43 per fully diluted share for the first nine months of 2006.

"Omnicell delivered another quarter of solid financial performance as demonstrated by our earnings, with new customers expressing their confidence in our solutions," said Randall A. Lipps, Omnicell president and chief executive officer. "We remain focused on delivering the best customer experience in healthcare and help our customers to continually improve patient safety."

Omnicell Conference Call Information

Omnicell will hold a conference call today at 2:30 p.m. PDT to discuss third quarter financial results. The number is 1-888-803-5209 within the U.S. or 1-706-679-1978 for all other locations. Internet users can access the conference call at A replay of the call will be available today at approximately 5:30 p.m. PDT and will be available for one week or until October 25. The replay access numbers are 1-800-642-1687 within the U.S. and 1-706-645-9291 for all other locations, passcode 19980216#.

About Omnicell

Omnicell, Inc. (Nasdaq: OMCL) is a leading provider of system solutions to acute healthcare facilities. Since 1992, Omnicell has worked to enhance patient safety and allow clinicians to spend more time with their patients.

Omnicell's medication-use product line includes solutions for the central pharmacy, nursing unit, operating room, and patient bedside. Solutions range from large central pharmacy "smart inventory" carousels to small handheld devices. From the point at which a medication arrives at the receiving dock to the time it is administered, Omnicell systems store it, package it, bar code it, order it, issue it, and provide information and controls on its use and reorder.

Omnicell's supply product lines provide a healthcare institution with fast, effective control of costs, capture of charges for payer reimbursement, and timely reorder of supplies. Products range from high-security closed- cabinet systems and software to open-shelf and combination solutions in the nursing unit, cath lab and operating room.

Omnicell's mission is to provide the best customer experience in healthcare, helping hospitals reduce medication errors, operate more efficiently, and decrease costs. For more information, visit

Forward-Looking Statements

To the extent any statements contained in this release deal with information that is not historical, these statements are necessarily forward-looking. As such, they are subject to the occurrence of many events outside Omnicell's control and are subject to various risk factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statement. The risk factors are described in Omnicell's filings with the Securities and Exchange Commission (SEC) and include, without limitation, the continued growth and acceptance of our products and services and the continued growth of the clinical automation and workflow automation market generally, the potential of increasing competition, the ability of Omnicell to achieve profitability in the next few quarters, grow product backlog, retain key personnel, cut expenses, develop new products and integrate acquired products or intellectual property in a timely and cost-effective manner, and improve sales productivity. Prospective investors are cautioned not to place undue reliance on forward-looking statements.

Use of Non-GAAP Financial Information

This press release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP). Our management evaluates and makes operating decisions using various performance measures. In addition to Omnicell's GAAP results, we also consider non-GAAP gross margin, non-GAAP operating expenses, non-GAAP net income (loss), and non-GAAP earnings (loss) per share diluted. These non-GAAP results should not be considered as an alternative to gross margin, operating expenses, net income, earnings per fully diluted share, or any other performance measure derived in accordance with GAAP. We present these non-GAAP results because we consider them to be important supplemental measures of Omnicell's performance.

Our non-GAAP gross margin, non-GAAP operating expenses, non-GAAP net income, non-GAAP earnings per fully diluted share are exclusive of certain items to facilitate management's review of the comparability of Omnicell's core operating results on a period to period basis because such items are not related to Omnicell's ongoing core operating results as viewed by management. We define our "core operating results" as those revenues recorded in a particular period and the expenses incurred within that period that directly drive operating income in that period. Management uses these non-GAAP financial measures in making operating decisions because, in addition to meaningful supplemental information regarding operation performance, the measures give us a better understanding of how we should invest in research and development, fund infrastructure growth and evaluate marketing strategies. In calculating the above non-GAAP results, management specifically adjusted for the following excluded items:

a) Stock-based compensation expense impact of SFAS 123R. We recognize

equity plan-related compensation expenses, which represent the fair

value of all share-based payments to employees, including grants of

employee stock options, as required under SFAS No. 123 (revised 2004),

"Share-Based Payment" (SFAS 123R).

b) Income tax benefit from tax valuation allowance release. This refers to

the recognition of an income tax benefit from the partial reversal of

our tax valuation allowance on specific deferred tax assets that is no

longer required. Under Statement of Financial Accounting Standards No.

109 (SFAS 109), the release of the tax valuation allowance is

necessary, primarily as a result of achieving sustained profitability

in certain tax jurisdictions.

Management adjusts for the excluded items because management believes that, in general, these items possess one or more of the following characteristics: their magnitude and timing is largely outside of Omnicell's control; they are unrelated to the ongoing operation of the business in the ordinary course; they are unusual and we do not expect them to occur in the ordinary course of business; or they are non-operational, or non-cash expenses involving stock option grants.

We believe that the presentation of these non-GAAP financial measures is warranted for several reasons:

1) Such non-GAAP financial measures provide an additional analytical tool

for understanding Omnicell's financial performance by excluding the

impact of items which may obscure trends in the core operating results

of the business;

2) Since we have historically reported non-GAAP results to the investment

community, we believe the inclusion of non-GAAP numbers provides

consistency and enhances investors' ability to compare our performance

across financial reporting periods;

3) These non-GAAP financial measures are employed by Omnicell's management

in its own evaluation of performance and are utilized in financial and

operational decision making processes, such as budget planning and

forecasting; and

4) These non-GAAP financial measures facilitate comparisons to the

operating results of other companies in our industry, which use similar

financial measures to supplement their GAAP results, thus enhancing the

perspective of investors who wish to utilize such comparisons in their

analysis of our performance.

Set forth below are additional reasons why specific items are excluded from our non-GAAP financial measures:

a) While stock-based compensation calculated in accordance with SFAS 123R

constitutes an ongoing and recurring expense of Omnicell, it is not an

expense which requires cash settlement by Omnicell. We therefore

exclude these charges for purposes of evaluating core operating

results. Thus, our non-GAAP measurements are presented exclusive of

stock-based compensation expenses to assist management and investors in

evaluating our core operating results.

b) We present our reconciliation of non-GAAP financial measures on a net

of tax basis because the exact tax differences related to the timing

and deductibility of stock-based compensation, pursuant to the adoption

of SFAS 123R, is dependent upon the trading price of Omnicell's common

stock and the timing and exercise by employees of their stock options.

We analyze and measure operating results net of tax when evaluating

core operating results because the tax effect related to stock-based

compensation expenses is inconsistent in amount and frequency.

c) We concluded under SFAS 109 that a portion of our tax valuation

allowance on specific deferred tax assets was no longer required,

primarily as a result of achieving sustained profitability in certain

tax jurisdictions. Therefore, we reversed a portion of our tax

valuation allowance which favorably impacted income tax expense and net


As stated above, we present non-GAAP financial measures because we consider them to be important supplemental measures of performance. However, non-GAAP financial measures have limitations as an analytical tool and should not be considered in isolation or as a substitute for Omnicell's GAAP results. In the future, we expect to incur expenses similar to the non-GAAP adjustments described above and expect to continue reporting non-GAAP financial measures excluding such items. Some of the limitations in relying on non-GAAP financial measures are:

-- Omnicell's stock option and stock purchase plans are important

components of incentive compensation arrangements and will be reflected

as expenses in Omnicell's GAAP results for the foreseeable future

under SFAS 123R.

-- Other companies, including other companies in Omnicell's industry, may

calculate non-GAAP financial measures differently than Omnicell,

limiting their usefulness as a comparative measure.

Pursuant to the requirements of SEC Regulation G, a detailed reconciliation between the company's GAAP and non-GAAP financial results is set forth in the financial statements at the end of this press release. Investors are advised to carefully review and consider this information strictly as a supplement to the GAAP results that are contained in this press release and in the Company's SEC filings.

Omnicell, Inc.

Condensed Consolidated Statement of Operations

(in thousands, except for per share data, unaudited)

Three Months Ended Nine Months Ended

September September June 30, September September

30, 2007 30, 2006 2007 30, 2007 30, 2006


Product $46,376 $33,239 $42,654 $129,271 $88,202

Services and other

revenues 8,776 7,992 9,168 25,864 23,422

Total revenue 55,152 41,231 51,822 155,135 111,624

Cost of revenues:

Cost of product

revenues 20,479 15,383 19,556 58,776 40,511

Cost of services and

other revenues 4,860 3,317 4,917 13,955 9,714

Total cost of revenues 25,339 18,700 24,473 72,731 50,225

Gross profits 29,813 22,531 27,349 82,404 61,399

Operating expenses:

Research and

development 3,848 2,878 3,766 10,999 7,858

Selling, general,

and administrative 20,732 16,736 19,402 58,497 48,031

Total operating expenses 24,580 19,614 23,168 69,496 55,889

Income from operations 5,233 2,917 4,181 12,908 5,510

Other income and expense 2,055 583 1,273 4,075 1,277

Income before provision

for income taxes 7,288 3,500 5,454 16,983 6,787

(Benefit from)

provision for income

taxes 348 384 (12,639) (12,015) 522

Net income $6,940 $3,116 $18,093 $28,998 $6,265

Net income per share:

Basic $0.20 $0.11 $0.58 $0.93 $0.23

Diluted $0.19 $0.11 $0.55 $0.88 $0.22

Shares used in

computing net income

per share:

Basic 34,127 27,775 31,003 31,278 27,336

Diluted 35,833 29,450 32,830 32,996 28,795

Omnicell, Inc.

Condensed Consolidated Balance Sheet

(In thousands)

September 30, June 30,

2007 2007 December, 31

(unaudited) (unaudited) 2006 (1)

Current Assets:

Cash and cash equivalents $175,748 $172,137 $60,856

Accounts receivable, net 46,927 36,799 34,021

Inventories 12,665 14,124 15,724

Prepaid expenses 9,273 7,575 8,033

Current deferred tax asset 7,973 8,111 ---

Other current assets 5,782 5,746 9,183

Total current assets 258,368 244,492 127,817

Property and equipment, net 7,945 5,246 5,226

Non-current net investment in

sales-type leases 11,257 12,265 12,244

Non-current deferred tax asset 4,810 4,796 ---

Other assets 12,534 10,873 9,343

Total Assets $294,914 $277,672 $154,630

Current Liabilities:

Accounts payable $9,749 $8,581 $8,792

Accrued compensation 7,532 8,417 7,702

Advance payments from customers 1,062 481 9,124

Accrued liabilities 5,276 4,577 5,174

Deferred service revenue 10,298 8,529 7,707

Deferred gross profit

SOURCE Omnicell, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Autopsy reports could be valuable and informative
2. China reports declining number of SARS Cases
3. Russia Reports First SARS Case
4. Research reports that c-section deliveries are rising
5. Jharkhand reports 13,000 Malaria cases
6. Uganda Reports Failure To Contain Sleeping Sickness
7. WHO reports 36 million deaths world wide due to chronic diseases
8. Reports of Hantavirus infection in India raise concerns
9. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
10. China Reports Yet Another Bird Flu Case
11. China reports seventh bird flu victim
Post Your Comments:
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... has recently contributed a medical article to the newly revamped Cosmetic Town ... article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
(Date:10/12/2017)... ... 12, 2017 , ... On Saturday, October 21, the Health & Wellness Center ... to raise money for the American Heart Association Heart Walk. Teams of up to ... together to keep their treadmills moving for 5 hours. Treadmills will start at 7:00 ...
(Date:10/12/2017)... ... 12, 2017 , ... In the United States, single-family home ... states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average is ... low property-tax rates, which contributes to the relatively lower cost of living in ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... Pepper Flow promotional review platform at the Promotional Review Committee Compliance and ... help marketers streamline the medical, legal, and regulatory review (MLR) process – ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... SAN DIEGO , Sept. 22, 2017 ... ll medical device is now successfully helping those with ... Union. Fibromyalgia diagnosed Amanda in ... getting dressed and washing my hair, experiencing no sleep ... body in painful spasm… I cannot recommend [the AVACEN ...
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
Breaking Medicine Technology: